Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-26T04:36:22.315Z Has data issue: false hasContentIssue false
  • English
  • Français

Development of Tics in a Thirteen-Year-Old Male Following Atomoxetine Use

Published online by Cambridge University Press:  07 November 2014

Jessica Sears  and
Nitin C. Patel
Get access Rights & Permissions [Opens in a new window]

Abstract

Tics and Tourette syndrome are common comorbidities of patients diagnosed with attention-deficit/hyperactivity disorder (ADHD). One of the mainstay pharmacologic therapies for ADHD has been stimulants. However, this class of drugs has been associated with tic exacerbations, thus limiting their utility in this patients subgroup. Atomoxetine has been explored as an alternative treatment as one of the few non-stimulants available to treat ADHD. Early data identifies atomoxetine's influence on Tourette symptomatology to be not merely equivocal but potentially suppressive in the manifestation of tics. There are, however, case studies describing patients experiencing recurrences of tics following treatment with atomoxetine. We present a unique case of a patient, without any prior history of a movement disorder, who developed tics following a single dose of atomoxetine that did not improve until interventional therapy was initiated.

Type
Case Report
Information
CNS Spectrums , Volume 13 , Issue 4 , April 2008 , pp. 301 - 303
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Banaschewski, T, Roessner, V, Dittman, RW, Santosh, PJ, Rothenberger, A. Non stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry. 2004;13:102–116.Google Scholar
2.Mink, JW. Tic disorders. In: Bernard, M, ed. Current Management in Child Neurology. 2nd ed. Lewiston, NY: BC Decker; 2002:305–312.Google Scholar
3.Wernicke, JF, Kratochvil, CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry. 2002;63:50–55.Google Scholar
4.Lee, TW, Lee, TD, Lombroso, PJ, King, RA. Atomoxetine and tics in ADHD. J Am Acad Child Adolesc Psychiatry. 2004;43:1068–1069.Google Scholar
5.Barkley, RA. A review of stimulant drug research with hyperactivity children. J Child Psychol Psychiatry. 1977;18:137–165.Google Scholar
6.Barkley, RA, McMurray, MB, Edelbrock, CS, Robbins, K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86:184–192.Google Scholar
7.Greenhill, L. Attention deficit/hyperactivity disorder: the stimulants. Child Adolesc Psychiatr Clin North Am. 1995;4:123–168.Google Scholar
8.Swanson, J. Effect of stimulant medication on hyperactive children. A review of reviews. Except Child. 1993;60:154–162.Google Scholar
9.Wilens, TE, Spencer, TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am. 2000;9:573–603.Google Scholar
10.Wilens, TE, Biederman, J, Spencer, TJ, Prince, J. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. J Clin Psychopharmacol. 1995;15:270–279.Google Scholar
11.McCracken, JT, Sallee, FR, Leonard, HL, et al. Improvement of ADHD by atomoxetine in children with tic disorders. Study presented at: Annual Meeting of the American Academy of Child and Adolescent Psychiatry: Miami, Fla; 2003.Google Scholar
12.Ledbetter, M. Atomoxetine use associated with onset of a motor tic. J Child Adolesc Psychopharmacol. 2005;15:331–333.Google Scholar
13.Greenberg, L, Yellin, A, Spring, C, Metcalf, M. Clinical effects of impramine and methylphenidate in hyperactive children. Int J Ment Health. 1975;4:144–156.Google Scholar